NewAmsterdam Pharma Q3 EPS $(0.14) Beats $(0.51) Estimate, Sales $19.164M Beat $7.340M Estimate
Benzinga Newsdesk 6 days ago
NewsEarningsEarnings Beats
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72 percent. This is a 77.05 percent increase over losses of $(0.61) per share from
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72 percent. This is a 77.05 percent increase over losses of $(0.61) per share from the same period last year. The company reported quarterly sales of $19.164 million which beat the analyst consensus estimate of $7.340 million by 161.09 percent. This is a 5.41K percent increase over sales of $348.000 thousand the same period last year.